Recent Updates
Recently added Catalysts

DT120

Phase 3

Major Depressive Disorder | Small molecule | Psychiatry |Definium Therapeutics, Inc.|Last Updated: Jun 29, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials2
Total Enrollment314
FDA Designations
No designations recorded
Clinical trial landscape

DT120 · 4 trials · 2 indications

Phase 3 4
NCT07592689A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)Major Depressive Disorder
RECRUITING165 Analytics
NCT06941844A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)Major Depressive Disorder
ACTIVE NOT_RECRUITING149 Analytics
NCT06809595A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)Generalized Anxiety Disorder
ACTIVE NOT_RECRUITING245 Analytics
NCT06741228A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)Generalized Anxiety Disorder
ACTIVE NOT_RECRUITING214 Analytics
PHASE3RECRUITING
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
Major Depressive DisorderUnlock trial analytics
PHASE3ACTIVE NOT_RECRUITING
A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)
Major Depressive DisorderUnlock trial analytics
PHASE3ACTIVE NOT_RECRUITING
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
Generalized Anxiety DisorderUnlock trial analytics
PHASE3ACTIVE NOT_RECRUITING
A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)
Generalized Anxiety DisorderUnlock trial analytics
Study Endpoints
Primary Endpoints
Change from Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6
Baseline to Week 6

The MADRS is used to assess depression severity and to detect changes due to antidepressant treatment. The MADRS includes 10 clinician-completed items. Each of the 10 questions is scored with a range of 0-6 points. An item score of 0 indicates item not present or normal, while an item score of 6 indicates severe or continuous presence of the symptoms. The total possible score is 60, and higher scores represent a more severe condition.

Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12
Baseline to Week 12

The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

Secondary Endpoints
Change from Baseline in the MADRS total score at Week 12, Week 4, Week 2, and Week 1
Week 12, Week 4, Week 2, and Week 1
MADRS response (reduction from Baseline score of ≥50%) at each timepoint assessed during the 12-week double-blind period
Baseline to Week 12
MADRS remission (total score ≤12) at each timepoint assessed during the 12-week double-blind treatment period
Baseline to Week 12
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Arm 1 - PlaceboPLACEBO_COMPARATORA substance that is designed to have no therapeutic value
Arm 2 - 50µg DT120SHAM_COMPARATORA psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
Arm 3 - 100µg DT120EXPERIMENTALA psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
Arm 2 - 100µg DT120EXPERIMENTALA psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
Interventions
NameTypeDescription
PlaceboOTHERA substance that is designed to have no therapeutic value
DT120DRUGA psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to 74 Years
SexALL
Healthy VolunteersNo
Study Sites27

Inclusion Criteria: 1. Diagnosis of MDD per DSM-5 2. Male or female aged 18 to 74 3. Currently experiencing a major depressive episode (MDE) of ≥8 weeks and ≤24 months duration 4. MADRS Total Score ≥26 5. CGI-S Score ≥4 Exclusion Criteria: 1. Certain psychiatric disorders (other than major depres...

Countries:United StatesCzechiaFranceGermanyPolandUnited Kingdom
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWJun 29, 2026NCT07592689lastUpdatePostDate: changed
LOWJun 29, 2026NCT06941844lastUpdatePostDate: changed
LOWJun 29, 2026NCT07592689lastUpdatePostDate: changed
LOWJun 29, 2026NCT06941844lastUpdatePostDate: changed
LOWJun 22, 2026NCT07592689lastUpdatePostDate: changed
MEDIUMJun 22, 2026NCT06741228primaryCompletionDate: changed
MEDIUMJun 22, 2026NCT06941844primaryCompletionDate: changed
MEDIUMJun 22, 2026NCT06809595primaryCompletionDate: changed
LOWJun 22, 2026NCT07592689lastUpdatePostDate: changed
MEDIUMJun 22, 2026NCT06941844primaryCompletionDate: changed
MEDIUMJun 22, 2026NCT06809595primaryCompletionDate: changed
MEDIUMJun 22, 2026NCT06741228primaryCompletionDate: changed
LOWMay 28, 2026NCT07592689lastUpdatePostDate: changed
LOWMay 28, 2026NCT07592689lastUpdatePostDate: changed
LOWMay 26, 2026NCT07592689primaryCompletionDate: changed
LOWMay 26, 2026NCT06941844primaryCompletionDate: changed
MEDIUMMay 26, 2026NCT06809595Status: RECRUITING → ACTIVE_NOT_RECRUITING
MEDIUMMay 26, 2026NCT06741228Status: RECRUITING → ACTIVE_NOT_RECRUITING
LOWMay 24, 2026NCT07592689studyFirstPostDate: changed
LOWMay 24, 2026NCT06809595studyFirstPostDate: changed